Natalia Perekhvatova

CEO

Built Mitotech's mitochondrial pipeline from early science to clinical validation and commercial partnership. Structured $40M out-licensing deal with Essex Biotechnology. Prior: Citigroup, Amadeus. MBA, INSEAD.

John M. Barberich

CFO

Decades of biotech finance experience. Co-founder and CFO of ACADIA Pharmaceuticals (NASDAQ: ACAD). CFO, Omrix Biopharmaceuticals (acquired by J&J). CFO, Scriptgen (acquired by Roche). Acting CBO/CFO of Lumos Pharma (NASDAQ: LUMO). Venture Partner, Nordic Biotech.

Dr. Lawrence Friedhoff

Chief Clinical Officer

Led clinical development of six FDA-approved products generating over $4B in annual sales. Prior: Bristol-Myers Squibb, Eisai, Andrx Laboratories, Axovant. Academic positions at Cornell and Sloan-Kettering. MD, NYU School of Medicine; PhD, Columbia University.

Dr. Maxim Skulachev

Chief Scientific Officer

Thought leader in mitochondrial research. Leads core MoA research, formulation and preclinical efficacy. Heads new lead compound discovery. Prior: Mitolab (Israel), Icon Genetics (Germany). PhD, Molecular Biology.

Dr. Anton Petrov

Chief Operating Officer

Expert in drug development operations across US and EU. Leads study design and data interpretation. 20+ years in biotechnology operations and data analytics. Prior: BioDiscovery, Infoquant. PhD in statistics, University of Southern California; MBA, INSEAD.

Dr. Alex Schwarz

Manufacturing Lead (Advisor)

Seasoned drug development expert with deep CMC and regulatory expertise. Led API and drug manufacturing at Novartis, Baxter and Braeburn. PhD, University of Bonn.